CO6321224A2 - Preparacion solida de desintegracion oral que contiene granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico - Google Patents

Preparacion solida de desintegracion oral que contiene granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico

Info

Publication number
CO6321224A2
CO6321224A2 CO10125889A CO10125889A CO6321224A2 CO 6321224 A2 CO6321224 A2 CO 6321224A2 CO 10125889 A CO10125889 A CO 10125889A CO 10125889 A CO10125889 A CO 10125889A CO 6321224 A2 CO6321224 A2 CO 6321224A2
Authority
CO
Colombia
Prior art keywords
fine granules
oral disintegration
controlled release
pharmaceutical use
show
Prior art date
Application number
CO10125889A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Kurasawa
Yasuko Watanabe
Yoshihiro Omachi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6321224(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6321224A2 publication Critical patent/CO6321224A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO10125889A 2008-03-11 2010-10-11 Preparacion solida de desintegracion oral que contiene granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico CO6321224A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008061673 2008-03-11
JP2008334920 2008-12-26

Publications (1)

Publication Number Publication Date
CO6321224A2 true CO6321224A2 (es) 2011-09-20

Family

ID=40791576

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10125889A CO6321224A2 (es) 2008-03-11 2010-10-11 Preparacion solida de desintegracion oral que contiene granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico

Country Status (26)

Country Link
US (2) US9241910B2 (https=)
EP (1) EP2254556A2 (https=)
JP (1) JP5604304B2 (https=)
KR (1) KR20100129761A (https=)
CN (2) CN104127368A (https=)
AR (1) AR070863A1 (https=)
AU (1) AU2009224254A1 (https=)
BR (1) BRPI0909439A2 (https=)
CA (1) CA2717947C (https=)
CL (1) CL2009000557A1 (https=)
CO (1) CO6321224A2 (https=)
CR (1) CR11709A (https=)
DO (1) DOP2010000273A (https=)
EA (1) EA021792B1 (https=)
EC (1) ECSP10010538A (https=)
GE (1) GEP20135845B (https=)
IL (1) IL207989A0 (https=)
MA (1) MA32174B1 (https=)
MX (1) MX2010009824A (https=)
MY (1) MY173730A (https=)
NZ (1) NZ588407A (https=)
PE (2) PE20091620A1 (https=)
TW (1) TWI441658B (https=)
UY (1) UY31698A (https=)
WO (1) WO2009113703A2 (https=)
ZA (1) ZA201006679B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
CN102119027A (zh) * 2008-06-26 2011-07-06 麦克内尔-Ppc股份有限公司 含有药物活性剂的包衣颗粒
KR101565621B1 (ko) 2009-01-26 2015-11-03 신에쓰 가가꾸 고교 가부시끼가이샤 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20130216617A1 (en) * 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
MX2013007588A (es) * 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.
CN102716097A (zh) * 2012-05-29 2012-10-10 浙江华海药业股份有限公司 控制口腔崩解片药物释放速率的方法
FI126168B (en) * 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3257511B1 (en) * 2015-02-10 2018-10-24 FUJIFILM Corporation Orally disintegrating tablet and method for manufacturing same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6905972B2 (ja) * 2016-02-23 2021-07-21 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2017147318A1 (en) 2016-02-23 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
GB201607548D0 (en) * 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
CN110121342A (zh) * 2016-12-28 2019-08-13 富士胶片富山化学株式会社 医药组合物
KR102555664B1 (ko) * 2017-02-21 2023-07-18 이에이 파마 가부시키가이샤 과립 제제
JP7235193B2 (ja) * 2017-04-26 2023-03-08 大正製薬株式会社 固形組成物
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
CN111712235A (zh) 2018-01-16 2020-09-25 应用材料公司 金属氧化物包封的药物组合物及其制备方法
JP7108041B2 (ja) 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
WO2019156904A1 (en) * 2018-02-08 2019-08-15 Taiwanj Pharmaceuticals Co., Ltd. Pharmaceutical formulation for a solid dosage form of opioid receptor antagonists
CN113301957A (zh) 2019-01-31 2021-08-24 普渡制药公司 取代的喹喔啉型桥接哌啶化合物的多晶型形式
EP4021421A4 (en) 2019-08-27 2023-05-10 Applied Materials, Inc. VAPOR PHASE COATINGS FOR PHARMACEUTICAL SOLUTION CONTROL
EP4021423A4 (en) 2019-08-27 2023-11-08 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
CN112121067A (zh) * 2020-11-16 2020-12-25 深圳科兴药业有限公司 一种婴儿型双歧杆菌微胶囊及其制备方法
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
MX2023013514A (es) 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
WO2023056304A1 (en) 2021-09-30 2023-04-06 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications
JPWO2023182332A1 (https=) * 2022-03-22 2023-09-28
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder
CN117180213A (zh) * 2023-10-23 2023-12-08 湖南洞庭药业股份有限公司 奥沙西泮片组合物及其制备和稳定化方法
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN117860699A (zh) * 2024-01-07 2024-04-12 长沙晶易医药科技股份有限公司 一种细粒剂及其制备方法
KR20260019740A (ko) * 2024-08-02 2026-02-10 일양약품주식회사 일라프라졸, 제산제 및 알칼리화제를 포함하는 안정한 약제학적 조성물 및 이의 제조방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69934505T2 (de) 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. Im munde zerfallende tablette enthaltend ein benzimidazole
TW585786B (en) 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US6897205B2 (en) 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
AU2002316020B2 (en) 2001-07-16 2007-03-15 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
KR20060065632A (ko) 2003-07-17 2006-06-14 닥터 레디스 래보러토리즈, 인코포레이티드 팽창성 코팅을 갖는 약제학적 조성물
NZ546183A (en) 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
GB0323232D0 (en) * 2003-10-03 2003-11-05 Rolls Royce Plc Electrical machine
WO2005079752A2 (en) 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CA2558535A1 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
EP1721604A4 (en) 2004-03-04 2008-04-30 Takeda Pharmaceutical STABLE CAPSULE PREPARATION
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
WO2006070845A1 (ja) 2004-12-28 2006-07-06 Eisai R & D Management Co., Ltd. 速崩壊性錠剤及びその製造方法
GB0502479D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
FR2885526B1 (fr) 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
EP1901719A2 (en) 2005-07-11 2008-03-26 Nycomed Danmark ApS Benzimidazole formulation
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US20090148519A1 (en) 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
EP1962844A2 (en) 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US8486450B2 (en) 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
KR100762847B1 (ko) 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1837016A3 (en) 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
US20090068263A1 (en) 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
HUE029173T2 (hu) 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
EP2614818A1 (en) 2006-04-28 2013-07-17 Wockhardt Limited Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
US20090291136A1 (en) 2006-07-11 2009-11-26 Lek Pharmaceuticals D.D. Multiple Unit Tablets
EP2068837A2 (en) 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
EP2098250B1 (en) 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
DK2152250T3 (da) 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
US20100015239A1 (en) 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same
MX2013007588A (es) 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.

Also Published As

Publication number Publication date
MY173730A (en) 2020-02-18
UY31698A (es) 2009-11-10
CR11709A (es) 2010-11-04
EA201071054A1 (ru) 2011-04-29
CN104127368A (zh) 2014-11-05
CA2717947A1 (en) 2009-09-17
CN102026627B (zh) 2016-10-26
JP2011513204A (ja) 2011-04-28
WO2009113703A3 (en) 2010-06-17
PE20091620A1 (es) 2009-11-12
ZA201006679B (en) 2011-11-30
EP2254556A2 (en) 2010-12-01
PE20141034A1 (es) 2014-09-10
CN102026627A (zh) 2011-04-20
KR20100129761A (ko) 2010-12-09
US9241910B2 (en) 2016-01-26
US20110091563A1 (en) 2011-04-21
EA021792B1 (ru) 2015-09-30
DOP2010000273A (es) 2010-09-30
TWI441658B (zh) 2014-06-21
NZ588407A (en) 2012-07-27
AU2009224254A1 (en) 2009-09-17
BRPI0909439A2 (pt) 2015-12-15
CA2717947C (en) 2020-07-07
GEP20135845B (en) 2013-06-10
US20150037423A1 (en) 2015-02-05
CL2009000557A1 (es) 2010-10-01
MA32174B1 (fr) 2011-03-01
TW200944249A (en) 2009-11-01
AU2009224254A2 (en) 2010-11-18
JP5604304B2 (ja) 2014-10-08
IL207989A0 (en) 2010-12-30
MX2010009824A (es) 2010-09-28
ECSP10010538A (es) 2010-11-30
WO2009113703A2 (en) 2009-09-17
AR070863A1 (es) 2010-05-12

Similar Documents

Publication Publication Date Title
CO6321224A2 (es) Preparacion solida de desintegracion oral que contiene granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
CR20140019A (es) Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia real crónica, contractura capsular mamaria y ...
AU2010308458A8 (en) Orally transformable tablets
PE20080765A1 (es) Formas de dosificacion farmaceutica
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2013003286A (es) Tableta de multiples capas de desintegracion oral y su elaboracion.
WO2011101866A3 (en) Gastric retention formulation containing baclofen
CL2011001817A1 (es) Forma de dosificacion unitaria solida oral en forma de tableta que comprende un nucleo y un recubrimiento externo, en donde el nucleo comprende alisquireno o a una sal del mismo, y el recubrimiento en un recubrimiento de pelicula, util para el tratamiento de una enfermedad o condicion en una poblacion pediatrica.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
PH12012502082A1 (en) Combination of active loaded granules with additional actives
PH12016500693B1 (en) Slow-release solid oral compositions
PH12016501756A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
PH12015501294A1 (en) A combination medicament comprising phenylephrine and paracetamol
ES2492673T3 (es) Formas cristalinas de un ingrediente farmacéutico activo
WO2016108507A3 (ko) 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
GT200700005A (es) Composicion farmaceutica estable de carisoprodol y meloxicam
PH12013502120A1 (en) Controlled release type tablet containing aceclofenac
PE20140675A1 (es) Comprimido farmaceutico de liberacion controlada para administracion oral
TN2010000411A1 (en) Orally-disintegrating solid preparation
UA93286C2 (ru) Комбинированный препарат анальгетического, противоспалительного и жаропонижающего действия, его кристалический coctab

Legal Events

Date Code Title Description
FC Application refused